Related references
Note: Only part of the references are listed.Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
Liqiang Xi et al.
BLOOD (2012)
The evolving contribution of hematopoietic progenitor cells to lymphomagenesis
Oliver Weigert et al.
BLOOD (2012)
Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Gilles Salles et al.
BLOOD (2012)
The B-cell receptor signaling pathway as a therapeutic target in CLL
Jennifer A. Woyach et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells
Emma Hamilton et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis
Sandrine Sander et al.
CANCER CELL (2012)
A Missing Link in Genotype-Directed Cancer Therapy
Rene Bernards
CELL (2012)
Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2012)
Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations
Tim M. Illidge
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
miR-125b and miR-155 Contribute to BCL2 Repression and Proliferation in Response to CD40 Ligand (CD154) in Human Leukemic B-cells
Shaun Willimott et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia
Loren D. Walensky
JOURNAL OF CLINICAL ONCOLOGY (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
Andrew R. Pettitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
BRAF Inhibition in Refractory Hairy-Cell Leukemia
Sascha Dietrich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice
Carolina Vicente-Duenas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Safety and efficacy of of atumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukaemia
Martin J. S. Dyer
THERAPEUTIC ADVANCES IN HEMATOLOGY (2012)
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
Margot Jak et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia
Yoshikane Kikushige et al.
CANCER CELL (2011)
Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia
Leisl M. Packer et al.
CANCER CELL (2011)
Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Philip C. Amrein et al.
CLINICAL CANCER RESEARCH (2011)
Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways
Laura B. Ramsey et al.
IMMUNOLOGY LETTERS (2011)
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S. Hart et al.
LEUKEMIA (2011)
Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway
Robert M. Anthony et al.
NATURE (2011)
Initial genome sequencing and analysis of multiple myeloma
Michael A. Chapman et al.
NATURE (2011)
BRAF Mutations in Hairy-Cell Leukemia
Enrico Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia
Ulf Klein et al.
CANCER CELL (2010)
The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma
Noraidah Masir et al.
HISTOPATHOLOGY (2010)
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Leandro C. Cerchietti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler et al.
BLOOD (2009)
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Nathalie A. Johnson et al.
BLOOD (2009)
Is Anticancer Drug Development Heading in the Right Direction?
Trevor W. Hambley
CANCER RESEARCH (2009)
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis
Satoshi Inoue et al.
MOLECULAR CANCER THERAPEUTICS (2009)
OPINION More is less-combining targeted therapies in metastatic colorectal cancer
Cornelis J. A. Punt et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Do molecularly targeted agents in oncology have reduced attrition rates?
Ian Walker et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL
Feng-Ting Liu et al.
BLOOD (2008)
Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver
Xandra Volkmann et al.
HEPATOLOGY (2007)
TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2
Alessandro Natoni et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Barriers to effective TRAIL-targeted therapy of malignancy
Martin J. S. Dyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Tumor growth need not be driven by rare cancer stem cells
Priscilla N. Kelly et al.
SCIENCE (2007)
The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral
David J. J. de Gorter et al.
JOURNAL OF IMMUNOLOGY (2007)
TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies
M MacFarlane et al.
CANCER RESEARCH (2005)
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma:: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes
F Rubio-Moscardo et al.
BLOOD (2005)
Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death
GV Georgakis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways
AS Kamiguti et al.
ONCOGENE (2003)
Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia
M MacFarlane et al.
ONCOGENE (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
